Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $649.1 million.

  • Revolution Medicines' Total Non-Current Liabilities rose 234.70% to $649.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $649.1 million, marking a year-over-year increase of 234.70%. This contributed to the annual value of $289.9 million for FY2024, which is 26.60% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Total Non-Current Liabilities is $649.1 million, which was up 16.54% from $557.0 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Total Non-Current Liabilities registered a high of $649.1 million during Q3 2025, and its lowest value of $87.6 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $270.7 million, with a median of $193.9 million in 2024.
  • In the last 5 years, Revolution Medicines' Total Non-Current Liabilities declined by 8.31% in 2023 and then skyrocketed by 234.70% in 2025.
  • Revolution Medicines' Total Non-Current Liabilities (Quarterly) stood at $134.8 million in 2021, then declined by 6.19% to $126.4 million in 2022, then skyrocketed by 81.11% to $229.0 million in 2023, then increased by 26.60% to $289.9 million in 2024, then spiked by 234.70% to $649.1 million in 2025.
  • Its last three reported values are $649.1 million in Q3 2025, $557.0 million for Q2 2025, and $283.1 million during Q1 2025.